Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting the VALOR-CKD clinical trial to evaluate the efficacy and safety of veverimer in delaying CKD progression…More in subjects with metabolic acidosis. There are no FDA-approved treatments for chronic metabolic acidosis.